New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:10 EDTBGMD, SNTA, SSYS, GES, TLYS, BURL, GSK, DDD, CIDM, LEN, FSLR, XONEOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Burlington Stores (BURL), up 5%... Lennar (LEN), up 2%... BG Medicine (BGMD), up 16%. ALSO HIGHER: Synta Pharmaceuticals (SNTA), up 20% after announcing positive interim results from ganetespib trial... First Solar (FSLR), up 3.5% after the company's price target was raised at Deutsche Bank, JPMorgan and RW Baird following the company issued it FY15 outlook yesterday. DOWN AFTER EARNINGS: Guess (GES), down 5%... Tilly's (TLYS), down 7%... ExOne (XONE), down 12%. Peers in 3D space down as well, with 3D Systems down 3% and Stratasys (SSYS) down 2%. ALSO LOWER: Agenus (AGEN), down 18% after announcing that GlaxoSmithKline’s (GSK) MAGRIT study, which contains Agenus’QS-21 Stimulon adjuvant, did not meet its first or second co-primary endpoint... Cinedigm Digital (CIDM), down 12% after filing to sell common stock.
News For GES;XONE;DDD;SSYS;FSLR;GSK;SNTA;LEN;BURL;BGMD;CIDM;TLYS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2015
07:01 EDTSSYSStratasys withdraws FY15 guidance
Subscribe for More Information
06:58 EDTSSYSStratasys reports Q2 non-GAAP EPS 15c, consensus 15c
Subscribe for More Information
July 29, 2015
14:49 EDTGSKGlaxoSmithKline probing new bribery allegations in Romania, Reuters reports
Subscribe for More Information
10:00 EDTDDDOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: 3D Systems (DDD) upgraded to Neutral from Underperform at Longbow... AK Steel (AKS) upgraded to Outperform from Neutral at Macquarie... Ally Financial (ALLY) upgraded to Outperform from Neutral at Credit Suisse... Amazon.com (AMZN) upgraded to Buy from Hold at Stifel... Arrow Electronics (ARW) upgraded to Buy from Underperform at CLSA... Beacon Roofing (BECN) upgraded to Buy from Neutral at CL King... Citrix (CTXS) upgraded to Outperform at Baird... Commvault (CVLT) upgraded to Buy from Hold at Jefferies... FireEye (FEYE) upgraded on positive checks, business mdoel changes at Oppenheimer... Hibbett Sports (HIBB) upgraded to Neutral from Underperform at Sterne Agee CRT... Integra LifeSciences (IART) upgraded to Outperform at Raymond James... M/A-COM (MTSI) upgraded to Buy from Hold at Needham... Norsk Hydro (NHYDY) upgraded to Neutral from Underperform at Exane BNP Paribas... NuVasive (NUVA) upgraded to Outperform from Market Perform at Northland... SM Energy (SM) upgraded to Outperform from Market Perform at Raymond James... Scorpio Bulkers (SALT) upgraded to Buy from Hold at Deutsche Bank... Sirius XM (SIRI) upgraded to Buy from Hold at Wunderlich... Sprouts Farmers Markets (SFM) upgraded to Neutral from Underperform at Longbow... Supervalu (SVU) upgraded to Equal Weight from Underweight at Morgan Stanley... Waters (WAT) upgraded to Outperform from Market Perform at Wells Fargo... Wells Fargo (WFC) upgraded to Buy from Neutral at Guggenheim... Williams-Sonoma (WSM) upgraded to Overweight from Neutral at JPMorgan... YRC Worldwide (YRCW) upgraded to Strong Buy at Raymond James.
08:00 EDTGSKGlaxoSmithKline reports Q2 global pharmaceuticals revenue GBP2.98B, down 12%
Reports Q2 HIV revenue GBP559M, up 59%. Reports Q2 Pharmaceuticals revenue GBP3.54B, down 6%, and vaccines revenue GBP814M, up 11%. Consumer healthcare sales were GBP1.51B, up 51% year over year.
07:58 EDTGSKGlaxoSmithKline sees FY16 core EPS to grow in double digits
Subscribe for More Information
07:57 EDTSSYSCanaccord remains cautious on Stratasys heading into Q2 results
Subscribe for More Information
07:57 EDTGSKGlaxoSmithKline reaffirms FY15 core EPS declining at high-teens percentage rate
Subscribe for More Information
07:54 EDTGSKGlaxoSmithKline reports Q2 adjusted EPS 17.3p, consensus 16.78p
Subscribe for More Information
07:22 EDTFSLRFirst Solar pullback since June a buying opportunity, says JPMorgan
JPMorgan analyst Paul Coster views the 20% pullback in shares of First Solar since mid June as a buying opportunity. Coster keeps an Overweight rating on the stock ahead of the company's Q2 results. He looks for Firs Solar's FY15 guidance, which was suspended since the company announced its intentions to form a YieldCo, to be reinstated. The analyst has a $68 price target on shares.
06:16 EDTDDD3D Systems upgraded to Neutral from Underperform at Longbow
Subscribe for More Information
July 28, 2015
07:50 EDTDDD, SSYSJefferies cuts price targets in 3D printing space after survey
After surveying 30 resellers in the 3D printing space, Jefferies analyst Jason North cut his price target for 3D Systems (DDD) to $14 from $22 and Stratasys (SSYS) to $50 from $60. A key investor discussion is when or if the industry will return to 20% growth, North writes in a research note. His survey indicates Q4 as the most likely time frame for Stratasys and later, if ever, for 3D Systems. The survey suggests weak Q2 results and a "muted" rebound in Q3, North tells investors. He prefers shares of Arcam (AMAVF) and Stratasys, both of which are Buy rated, to Hold-rated 3D Systems and Proto Labs (PRLB).
July 27, 2015
17:31 EDTGSKRadius Health hires Dr. Lorraine Fitzpatrick as Chief Medical Officer
Radius Health (RDUS) announced that it has hired Dr. Lorraine A. Fitzpatrick as Chief Medical Officer of the Company. Dr. Fitzpatrick was previously Medicine Development Leader of an international clinical development team for Denosumab at GlaxoSmithKline (GSK), responsible for clinical development, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. Previously, Dr. Fitzpatrick led the clinical development of novel agents to treat musculoskeletal diseases and women's health at GlaxoSmithKline. Before joining GlaxoSmithKline, Dr. Fitzpatrick was Executive Director at Amgen, Inc. where she worked in the fields of osteoporosis and oncology.
17:07 EDTFSLRSunPower acquires 1.5 gigawatt U.S. solar power plant pipeline
Subscribe for More Information
11:37 EDTSSYSStratasys upgraded to Buy with $45 price target at Dougherty
Before the open, Dougherty analyst Andrea James upgraded Stratasys (SSYS) to Buy from Neutral and set a $45 price target on the stock, noting that the firm's North American channel checks indicate the sales climate has improved since the stock was downgraded in April. James also said that the pullback in the stock over that time frame leaves it trading at a "historically low P/E multiple" and that the firm believes HP (HPQ) will compete more directly with others in the 3D space than it will with Stratasys.
08:03 EDTGSKNephroGenex names Jaikrishna Patel as Chief Medical Officer
NephroGenex (NRX) announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the company’s Phase 3 PIONEER program with oral Pyridorin for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline (GSK) and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs.
July 24, 2015
11:01 EDTFSLRSolarCity rises after analyst says second half outlook strong
Subscribe for More Information
05:04 EDTGSKAgenus reports GSK Malaria vaccine receives positive opinion from CHMP of EMA
Subscribe for More Information
July 23, 2015
10:24 EDTDDDZVerse announces strategic partnership and commercial agreement with 3D Systems
Subscribe for More Information
July 22, 2015
08:38 EDTBURLNRF cuts 2015 retail sales growth forecast to 3.5% from 4.1%
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use